Skip to main content
Nanjing Hicin Pharmaceutical CO.,LTD. logo

Nanjing Hicin Pharmaceutical CO.,LTD. — Investor Relations & Filings

Ticker · 300584 ISIN · CNE100002F44 LEI · 3003008BJ5O4E3OCKN40 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 959 across all filing types
Latest filing 2026-05-27 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300584

About Nanjing Hicin Pharmaceutical CO.,LTD.

https://www.hicin.cn

Nanjing Hicin Pharmaceutical CO.,LTD. specializes in the research, development, manufacturing, and commercialization of chemical drug preparations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio focusing on therapeutic areas such as cardiovascular and cerebrovascular diseases, digestive system disorders, anti-infectives, and endocrine health. Its core offerings include specialized injectable formulations and high-purity APIs produced in compliance with international quality standards. By integrating advanced chemical synthesis technologies with modern pharmaceutical manufacturing processes, the company provides clinical solutions aimed at addressing complex medical needs. The organization emphasizes continuous innovation through its dedicated R&D centers, focusing on the development of generic drugs with high technical barriers and value-added formulations for healthcare markets.

Recent filings

Filing Released Lang Actions
江苏世纪同仁律师事务所关于公司2025年度股东会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a legal opinion letter by a law firm on the 2025 annual shareholders’ meeting, detailing the convening procedures, attendance qualifications, voting process, and, crucially, the precise vote counts and percentages for each resolution. This aligns with category DVA (Declaration of Voting Results & Voting Rights Announcements) which covers official results from shareholder votes at any general meeting.
2026-05-27 Chinese
2025年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document is an announcement of the shareholders’ meeting resolutions, detailing meeting attendance and vote results for each proposal from the 2025 Annual General Meeting. It does not present financial statements or an investor presentation, but rather the formal voting outcomes. This matches the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-27 Chinese
关于2026年度对下属子公司提供担保额度预计的公告
Capital/Financing Update Classification · 75% confidence The document is an official announcement by Nanjing Haichen Pharmaceutical Co., Ltd. regarding the expected guarantee limit of RMB 50 million provided to its wholly-owned subsidiary for financing purposes in 2026. It details the guarantee amount, terms, board approval, and subsidiary financials. This is a financing arrangement announcement (guarantee support) rather than a report of financial results, share issuance, or AGM materials. It best fits the Capital/Financing Update category.
2026-04-24 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "南京海辰药业股份有限公司2026年第一季度报告" which translates to "Nanjing Haichen Pharmaceutical Co., Ltd. 2026 First Quarter Report." It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and management commentary for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. There is no indication that this is an announcement or a certification; it is the full report itself. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-24 Chinese
独立董事2025年度独立性自查报告(陆涛)
Governance Information Classification · 85% confidence The document is an Independent Director Independence Self-Check Report of a listed company, detailing the director’s annual compliance with independence requirements under corporate governance rules. It is not announcing appointments, financial results, or dividends, nor is it an AGM presentation or audit report. Instead, it pertains to internal governance practices and board oversight. Therefore, it falls under Governance Information (Code: CGR).
2026-04-24 Chinese
独立董事2025年度独立性自查报告(毛凌霄)
Governance Information Classification · 75% confidence The document is titled “独立董事独立性自查报告” (Independent Director Independence Self-Assessment Report), consisting of an independent director’s annual self‐check against governance rules. It is not an AGM presentation, change announcement (MANG), financial or audit report, or earnings release. Rather, it documents governance practice/compliance under the company’s internal rules and securities regulations. Therefore it best fits Governance Information (CGR).
2026-04-24 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.